Intervontions of Interest:

  • etranacogene dezaparvovec (CSL Behring)
  • valoctocogene roxaparvovec (Roctavian ™; BioMarin)

ICER reviewed valoctocogene roxaparvovec for hemophilia A in 2020 (Valoctocogene Roxaparvovec and Emicizumab for Hemophilia A without Inhibitors: Effectiveness and Value). In this review, the two interventions will be considered separately as if we were performing two independent reviews in two different populations.

For questions, please contact Monica Frederick, Program Associate, at mfrederick@icer.org.

View the Key Stakeholder List.